LENZ Therapeutics Inc

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Solana Beach, CA.

After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.

LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President and CEO Shawn Olsson - CCO Marc Odrich - CMO Conference Call Participants Yigal Nochomovitz - Citi Marc Goodman - Leerink Partners Joe Catanzaro - Piper Sandler Pavan Patel - Bank of America Lachlan Hanbury-Brown - William Blair Gary Nachman - Raymond James Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call.

LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript

On Sunday, Corxel Pharmaceuticals and LENZ Therapeutics LENZ released topline data from the Phase 3 JX07001 trial of LNZ100 in patients with presbyopia in China.

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Acumen Pharmaceuticals

WALTHAM, Mass.--(BUSINESS WIRE)--Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. “It's an honor to lead LucyTx's Board. The company's non-traditional approach to deve.

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate.

LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks

LENZ Therapeutics (NASDAQ: LENZ ) just reported results for the first quarter of 2024. LENZ Therapeutics reported earnings per share of -$3.53.

LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President & CEO Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Pavan Patel - Bank of America Yigal Nochomovitz - Citigroup Joseph Catanzaro - Piper Sandler Marc Goodman - Leerink Lachlan Hanbury-Brown - William Blair Matthew Caufield - H. C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics Second Quarter 2024 Conference Call.

LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript

Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company has submitted a New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, August 14, 2024 at 4:30 p.m. ET to report its second quarter 2024 financial results and provide a business update.

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader (“KOL”) event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectives on LNZ100 data from the Phase 3 CLARITY study.

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City.

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President and CEO Dr. Marc Odrich - Chief Medical Officer Shawn Olsson - Chief Commercial Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Yigal Nochomovitz - Citigroup Tim Lugo - William Blair Basma Radwan - Leerink Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to LENZ Therapeutics First Quarter 2024 Financial Results and Business Update.

LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript

Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update.

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced positive topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly.

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that the Company will host a conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, r.

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Comstock Resources

Liberty Media Corp-Liberty SiriusXM

Nkarta, Inc.

Sirius XM Holdings Inc

Snowflake

ARS Pharmaceuticals Inc

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks.

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

Graphite Bio

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced the completion of its previously announced merger with Graphite Bio, Inc. (previously trading on Nasdaq under the ticker symbol “GRPH”) (“Graphite Bio”). The new combined company will operate under the name LENZ Thera.

News for LENZ Therapeutics Inc Stock (LENZ)